尼妥珠单抗联合FOLFIRI化疗治疗术后复发转移性结直肠癌的临床观察

目的：观察和评价表皮生长因子受体（EGFR）的单克隆抗体尼妥珠单抗（nimotuzumab）联合FOLFIRI化疗治疗术后复发转移性结直肠癌的近期疗效和不良反应。方法：入组患者为经手术治疗后复发转移性结直肠癌患者17例，应用尼妥珠单抗联合伊立替康＋亚叶酸钙＋氟尿嘧啶两周方案（FOLFIRI），尼妥珠单抗剂量200mg·m-1，每2周（200mg·m-1）1次维持。治疗4个周期后评价疗效。结果：全组17例完全缓解1例，部分缓解7例，稳定7例，进展2例，总有效率47．1％。不良反应主要是恶心呕吐、骨髓抑制、迟发性腹泻、胆碱能综合征等。结论：尼妥珠单抗联合FOLFIRI化疗治疗术后复发转移性结直肠癌疗效肯定，不良反应可耐受，可供临床安全使用。

Clinical Efficacy of Nimotuzumab Combined with FOLFIRI Chemotherapy for Postoperative Recurrent and Metastatic Colorectal Cancer

OBJECTIVE： To evaluate the short-term efficacy and safety of Nimotuzumab （monoclonal antibody of epidermal growth factor, EGFR） combined with FOLFIRI chemotherapy for postoperative recurrent and metastatic colorectal cancer. METHODS： Seventeen patients with postoperative recurrent and metastatic colorectal cancer were assigned to receive Nimotuzumab （200 mg· m-2 ） combined with FOLFIRI chemotherapy （ irinotecan ＋ FC ＋ 5-FU） every two weeks （per cycle）. The efficacy of therapy was evaluated after treatment of four cycles. RESULTS： The overall response rate of the total 17 cases was 47. 1% , 1 with complete remission, 7 partial remissions, 7 stable diseases and 2 progression. The major side effects included nausea and vomiting, myelosuppression, tardive diarrhea and cholinergic syndrome etc. CONCLUSION： Nimotuzumab combined with FOLFIRI chemotherapy is safe （with tolerable side effects） and effective for patients with postoperative recurrent and metastatic colorectal cancer.